Zobrazeno 1 - 10
of 492
pro vyhledávání: '"Masanori, Matsumoto"'
Autor:
Masanori Matsumoto, Akihiko Shimono, Jun Yokosawa, Keiichiro Hirose, Edward Wang, Shoichi Maruyama
Publikováno v:
Thrombosis Journal, Vol 22, Iss 1, Pp 1-11 (2024)
Abstract Background Atypical hemolytic uremic syndrome (aHUS) is a rare disease with poor outcomes when untreated, in which ravulizumab or eculizumab are the standard of care where available. It has been proposed to regularly monitor platelet counts
Externí odkaz:
https://doaj.org/article/3634c59e40ed4b91a154deff419fb061
Autor:
Kazunori Imada, Yoshitaka Miyakawa, Satoshi Ichikawa, Hitoji Uchiyama, Yasunori Ueda, Yasuhiro Hashimoto, Masashi Nishimi, Masako Tsukamoto, Sayaka Tahara, Masanori Matsumoto
Publikováno v:
Thrombosis Journal, Vol 22, Iss 1, Pp 1-8 (2024)
Abstract Background A recent Phase 2/3 study in Japanese patients showed that caplacizumab was effective in treating immune-mediated thrombotic thrombocytopenic purpura (iTTP), with a low rate of iTTP recurrence. ADAMTS13 activity is monitored weekly
Externí odkaz:
https://doaj.org/article/871d701cd0654ce9b4f10eafb205124e
Autor:
Shinya Yamada, Kazuya Sakai, Masayuki Kubo, Hirokazu Okumura, Hidesaku Asakura, Toshihiro Miyamoto, Masanori Matsumoto
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 8, Iss 5, Pp 102517- (2024)
Background: Transplant-associated thrombotic microangiopathy (TA-TMA) is a fatal complication of hematopoietic stem cell transplantation and is characterized by severe thrombocytopenia, hemolytic anemia, and organ dysfunction. In response to several
Externí odkaz:
https://doaj.org/article/a1a9a3301ad64cdabd86345a29d920a2
Autor:
Kazuya Sakai1, Masanori Matsumoto1,2
Publikováno v:
Japanese Journal of Transfusion & Cell Therapy / Nihon Yuketsu Saibo Chiryo Gakkaishi. 2024, Vol. 70 Issue 4, p485-491. 7p.
Autor:
Hideo Wada, Hirofumi Teranishi, Akihiko Shimono, Noritoshi Kato, Shoichi Maruyama, Masanori Matsumoto
Publikováno v:
Thrombosis Journal, Vol 21, Iss 1, Pp 1-12 (2023)
Abstract Background Atypical hemolytic uremic syndrome (aHUS) is caused by complement dysregulation and is generally diagnosed by exclusion from other disorders of thrombotic microangiopathy (TMA). Eculizumab, a terminal complement inhibitor, has bee
Externí odkaz:
https://doaj.org/article/66b814ce2378458b8ffc03d94ff1015a
Autor:
Tomonori Tadokoro, Keiko Ohta‐Ogo, Yoshihiko Ikeda, Masaya Sugiyama, Harutaka Katano, Kinta Hatakeyama, Masanori Matsumoto, Hideki Tashiro
Publikováno v:
ESC Heart Failure, Vol 10, Iss 2, Pp 1461-1466 (2023)
Abstract Coronavirus disease 2019 (COVID‐19) is often accompanied by pneumonia and can be fatal. We report a case of COVID‐19‐associated myocardial injury mimicking fulminant myocarditis. Endomyocardial biopsy revealed numerous von Willebrand f
Externí odkaz:
https://doaj.org/article/7ccc1b9b26c949b4bfa4ac5ab71cc315
Autor:
Nobushiro Nishimura MD, Kiyomi Yoshimoto MD, PhD, Noritaka Yada MD, PhD, Ayaka Kakiwaki MD, Akihiro Sawa MD, Satoshi Senzaki MD, Hiromasa Kawashima MD, Ryo Yoneima MD, Shiro Ono MD, PhD, Kazuya Sakai MD, PhD, Masanori Matsumoto MD, PhD, Hidetada Fukushima MD, PhD, Kenji Nishio MD, PhD
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis, Vol 29 (2023)
In some cases, differentiating thrombotic thrombocytopenic purpura (TTP) from septic disseminated intravascular coagulation (DIC) without measuring ADAMTS13 activity is critical for urgent lifesaving plasma exchange. To investigate whether PLASMIC sc
Externí odkaz:
https://doaj.org/article/e760b1a475bf492f8baa7e4f2add5119
Publikováno v:
Cell Reports, Vol 42, Iss 8, Pp 112973- (2023)
Summary: Neutrophils play a critical role in the eradication of Pseudomonas aeruginosa, a major pathogen causing lung infection. However, the mechanisms used by the pathogen to evade neutrophil-mediated killing remain poorly understood. Using a high-
Externí odkaz:
https://doaj.org/article/82866412688d41b6a9f478a23ed6f4ad
Autor:
Shu Kasama, Masanori Matsumoto, Midori Shima, Masato Kasahara, Keiji Nogami, Masahiro Takeyama, Naoki Ozu
Publikováno v:
BMJ Open, Vol 13, Iss 7 (2023)
Introduction Emicizumab prophylaxis substantially reduces bleeding episodes in patients with haemophilia A (HA). The haemostatic efficacy of emicizumab in patients with HA is estimated as approximately 15% based on mimic activity of factor (F) VIII.
Externí odkaz:
https://doaj.org/article/68408b4f1d2e47268d08d36422d59d3c
Autor:
Kikuaki Yoshida, Shogo Murata, Masaya Morimoto, Toshiki Mushino, Ken Tanaka, Yusuke Yamashita, Hiroki Hosoi, Akinori Nishikawa, Shinobu Tamura, Kinta Hatakeyama, Masanori Matsumoto, Takashi Sonoki
Publikováno v:
Hematology Reports, Vol 14, Iss 2, Pp 203-209 (2022)
A 49-year-old female was admitted to our hospital with malaise and gross hematuria. As ADAMTS13 (a disintegrin-like and metalloproteinase with thrombospondin type 1 motifs 13) activity was absent and the ADAMTS13 inhibitor was detected, she was diagn
Externí odkaz:
https://doaj.org/article/f0a06231f24f4b3b825ae27282bda44e